India Targeted Therapy Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Targeted Therapy Market was valued at USD 155.0 million in 2025 and is projected to reach USD 250.53 million by 2032, growing at a CAGR of approximately 7.1% during 2026–2032.
India Targeted Therapy Market Highlights
| Report Metric | Details |
| Report Name | India Targeted Therapy Market |
| Market Size 2025 | USD 155.0 million |
| Market Size 2032 | USD 250.53 million |
| Absolute Growth 2025–2032 | USD 95.53 million |
| CAGR 2026–2032 | 7.1% |
| Peak Annual Growth | 8.8% in 2031 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Therapy Type, 2025 | Biologic Therapies (33% share) |
| Leading Disease Indication, 2025 | Oncology (38% share) |
| Leading Delivery Mode, 2025 | Injection/IV (49% share) |
| Leading End User, 2025 | Hospitals (43% share) |
| Fastest-Growing Therapy Type | RNA-Based Therapies (9.0% CAGR) |
| Fastest-Growing Disease Indication | Genetic Disorders (8.8% CAGR) |
| Fastest-Growing Delivery Mode | Nucleic Acid Delivery (9.4% CAGR) |
| Fastest-Growing End User | Specialty Clinics (8.5% CAGR) |
| Growing Sector | Oncology |
| Key End Users | Hospitals, Specialty Clinics, Research Hospitals |
India Targeted Therapy Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
The following table presents the estimated annual growth rate for each year together with the principal factor influencing market performance.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 7.2 | The market showed strong demand with a growth rate reflecting ongoing cancer treatment advancements. |
| 2023 | 6.8 | Growth slowed due to increased treatment costs and regulatory challenges affecting approvals. |
| 2024 | 7.5 | Demand increased as more hospitals adopted advanced oncology technologies and therapies. |
| 2025 | 6.0 | Growth slowed again as budget constraints limited hospital expenditures on new treatments. |
| 2026 | 8.2 | The market surged with rising investments in targeted therapies and expanding clinical trials. |
| 2027 | 6.1 | Growth slowed as supply chain issues impacted the availability of certain therapies. |
| 2028 | 8.6 | Demand accelerated with the introduction of new RNA-based therapies and clinical successes. |
| 2029 | 5.0 | Growth slowed as competition intensified among therapy providers and pricing pressures emerged. |
| 2030 | 5.7 | Demand rose as more hospitals integrated targeted therapies into their treatment protocols. |
| 2031 | 8.8 | The market peaked with significant advancements in biologic therapies and patient access initiatives. |
| 2032 | 7.4 | Growth slowed as the market stabilised with established therapies dominating treatment options. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Targeted Therapy Market Synopsis
The Targeted Therapy Market in India includes advanced cancer treatments that specifically target cancer cells. This market is propelled by new therapies, with India's oncology sector anticipated to serve 1.5 million patients by 2025. The rising incidence of cancer and government initiatives, such as the National Cancer Control Programme, are driving this growth. The emphasis on biologic therapies, which represent about 30% of the market, is broadening treatment options for patients.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Rising prevalence of cancer leads to increased demand for effective treatment options. | Driver | High | Oncology |
| Government initiatives are funding research and development in targeted therapies. | Driver | High | Biologic Therapies |
| The growing number of hospitals equipped with oncology facilities creates a significant opportunity. | Opportunity | High | Hospitals |
| Emerging RNA-based therapies present new avenues for investment and development. | Opportunity | High | RNA-Based Therapies |
| High treatment costs limit access for low-income patients, constraining market growth. | Restraint | High | Biologic Therapies |
| Regulatory hurdles can delay the approval of new therapies, impacting availability. | Restraint | Medium | Biologic Therapies |
| Limited awareness among patients about targeted therapies slows adoption rates. | Challenge | Medium | Oncology |
| Supply chain disruptions affect the timely delivery of targeted therapies to hospitals. | Challenge | Medium | Biologic Therapies |
Evaluation of Drivers in India Targeted Therapy Market (2026–2032)
The main growth drivers and the segments they affect most are set out below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increasing patient numbers drive demand for targeted therapies in oncology. | Oncology | India's oncology market is expected to reach 1.5 million patients by 2025, leading to higher therapy purchases. |
| Government funding for cancer treatment initiatives boosts market growth. | Biologic Therapies | In 2022, the Indian government allocated INR 1,000 crore for cancer treatment initiatives, improving therapy availability. |
| Technological advancements in treatment methods improve patient outcomes. | RNA-Based Therapies | Over 50 clinical trials for RNA-based therapies are ongoing in India, increasing interest and investment in this area. |
| Growing hospital infrastructure supports the adoption of targeted therapies. | Hospitals | Over 200 hospitals in India are equipped with advanced oncology treatment facilities, facilitating therapy access. |
| Rising awareness of targeted therapies among healthcare professionals boosts demand. | Specialty Clinics | The Indian Council of Medical Research is funding targeted therapy research projects, promoting awareness and usage. |
The oncology market is projected to reach 1.5 million patients by 2025, driving demand for effective therapies. Ongoing clinical trials for RNA-based therapies are increasing interest and investment in this area. The presence of over 200 hospitals equipped with advanced oncology treatment facilities supports patient access to targeted therapies.
Evaluation of Restraints in India Targeted Therapy Market
The main factors holding the market back are set out below.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| High treatment costs limit access for many patients, affecting overall demand. | Biologic Therapies | The average treatment cost for targeted therapy in India ranges from INR 50,000 to INR 1,50,000 per month, restricting affordability. |
| Regulatory hurdles can delay the approval of new therapies, impacting availability. | Biologic Therapies | The Drug Controller General of India oversees approvals, which can slow market entry for new therapies. |
| Limited awareness among patients about targeted therapies slows adoption rates. | Oncology | Many patients remain unaware of targeted therapies and their benefits, hindering market growth. |
| Supply chain disruptions affect the timely delivery of targeted therapies to hospitals. | Biologic Therapies | Logistical challenges can delay the distribution of therapies, impacting patient treatment timelines. |
| Competition among therapy providers can lead to price wars, affecting profitability. | Specialty Clinics | As more clinics enter the market, pricing pressures may arise, impacting revenue for existing providers. |
India Targeted Therapy Market Challenges
The India Targeted Therapy Market faces notable technological challenges. Many rural hospitals lack advanced equipment, which hinders effective treatment delivery and prolongs patient suffering. A shortage of skilled oncology professionals complicates matters, resulting in longer wait times for patients seeking targeted therapies. Buyers encounter high costs, with average monthly treatment expenses ranging from INR 50,000 to INR 1,50,000, making these therapies unaffordable for many families. Lengthy approval processes under the Drugs and Cosmetics Act can delay the introduction of new therapies, restricting treatment options for hospitals and delaying patient access.
Trends in the India Targeted Therapy Market
The trends below show where the India Targeted Therapy Market is heading.
- Shift from Traditional to Targeted Therapies: Hospitals are increasingly adopting targeted therapies over traditional methods, improving treatment precision. The National Cancer Control Programme supports this shift, with a projected increase in patient access to targeted therapies.
- Emergence of RNA-Based Therapies: RNA-based therapies are gaining traction in India, with over 50 clinical trials currently ongoing. This trend reflects the growing focus on new treatment options, aiming to improve patient outcomes.
- Increased Funding for Cancer Research: The Indian government has increased funding for cancer research initiatives, particularly through the National Cancer Registry Programme. This investment aims to improve data collection and treatment strategies for targeted therapies.
- Adoption of Quality Standards in Healthcare: Healthcare facilities are increasingly adopting ISO 9001:2015 standards to ensure quality management in treatment delivery. This trend is critical for maintaining high standards in targeted therapy administration.
Investment Opportunities in the India Targeted Therapy Market
The following opportunities in the India Targeted Therapy Market pair current demand with a clear way in.
- Hospitals Seeking Advanced Treatment Options: With over 200 hospitals equipped for oncology, there is a growing demand for targeted therapies. The government allocated INR 1,000 crore for cancer treatment initiatives, creating an opportunity for suppliers.
- Timing for Investment in RNA-Based Therapies: The ongoing clinical trials for RNA-based therapies present a timely investment opportunity. Hospitals and specialty clinics are keen to adopt these therapies as they receive approval.
- Supply of Biologic Therapies to Specialty Clinics: Specialty clinics are increasingly focusing on biologic therapies, which constitute about 30% of the market. Forming partnerships with these clinics can facilitate entry into this segment.
- Entry through Government Initiatives: The 'Ayushman Bharat' scheme aims to provide health coverage for targeted therapy treatments to 500 million citizens. Collaborating with government agencies can assist suppliers in accessing this large market.
Government Initiatives in the India Targeted Therapy Market
The regulatory framework for targeted therapy in India is shaped by several key measures. The Drugs and Cosmetics Act governs the approval process for targeted therapies, ensuring safety and efficacy before market entry. In 2021, the Ministry of Health and Family Welfare introduced the National Policy for Rare Diseases to support targeted therapies for genetic disorders, broadening treatment options for patients. Additionally, the National Cancer Registry Programme was updated in 2020 to improve data collection on cancer treatments, including targeted therapies, which aids in better policy formulation. The government allocated INR 1,000 crore in 2022 to enhance cancer treatment initiatives, reflecting its commitment to improving healthcare access.
Healthcare providers benefit from various government schemes aimed at facilitating targeted therapy access. The 'Ayushman Bharat' scheme, launched in 2020, aims to provide health coverage for targeted therapy treatments to 500 million citizens, significantly expanding patient access. The Department of Biotechnology's 'Biotechnology Industry Research Assistance Council' initiated in 2022 funds targeted therapy research projects, encouraging progress in the sector. Furthermore, the Indian Council of Medical Research actively supports research projects in targeted therapies, ensuring that advancements in treatment continue to evolve. These initiatives improve the environment for targeted therapy in India, benefiting both providers and patients.
Future Insight of the India Targeted Therapy Market
By 2032, the India Targeted Therapy Market will experience substantial changes driven by key initiatives. The National Cancer Control Programme will broaden treatment access, improving infrastructure in underserved areas. Increased funding for cancer research will support the development of new therapies, with over 50 ongoing clinical trials for RNA-based therapies expected to yield new options. Enhanced quality management standards like ISO 9001:2015 will elevate patient care across healthcare facilities, ensuring safer and more effective treatment experiences.
Market Segmentation Analysis
The report offers a comprehensive study of the following market segments and their leading categories in the market.
By Therapy Type – Biologic Therapies Dominated, RNA-Based Therapies Expected to Grow Fastest
According to Sumit Sagar, AM at 6Wresearch, Biologic Therapies held a 33% share of the India Targeted Therapy Market by therapy type in 2025. Biologic therapies hold the largest share of the targeted therapy market in India due to their extensive use in treating various cancers and autoimmune disorders. With over 200 hospitals equipped for advanced oncology treatment, the demand for biologic therapies continues to rise. The quickest growth will come from RNA-Based Therapies, forecast to expand at a CAGR of 9.0% between 2026 and 2032. RNA-based therapies are experiencing rapid growth as they show promise in treating genetic disorders and cancers, with over 50 clinical trials currently ongoing in India. This burgeoning interest in RNA therapies is likely to attract more investment and research, further accelerating their adoption. Suppliers should focus on expanding their RNA-based therapy offerings to capitalise on the growing interest and potential market share.
By Disease Indication – Oncology Dominated, Genetic Disorders Expected to Grow Fastest
Oncology accounted for a 38% market share by disease indication in 2025. Oncology holds the largest share in the targeted therapy market in India, as it is the primary area of focus for treatment. The oncology sector is projected to support 1.5 million patients by 2025, showcasing the strong demand for targeted therapies. Genetic Disorders are set to record the highest CAGR in this split, 8.8% over 2026–2032. Genetic disorders are seeing the fastest growth due to increasing awareness and ongoing research initiatives. The Indian Council of Medical Research is funding numerous projects, which is likely to accelerate the adoption of targeted therapies for these conditions. Suppliers should anticipate a growing demand for targeted therapies that address genetic disorders as research initiatives expand.
By Delivery Mode – Injection/IV Dominated, Nucleic Acid Delivery Expected to Grow Fastest
With a 49% revenue share in 2025, Injection/IV was the largest delivery mode category. Injection/IV holds the largest share in the targeted therapy market in India due to its established role as the standard delivery method for many biologic therapies. This method is widely adopted in hospitals, ensuring that patients receive consistent and effective treatment. Nucleic Acid Delivery is projected to grow fastest, at a CAGR of 9.4% during 2026–2032. Nucleic Acid Delivery is witnessing rapid growth, primarily driven by ongoing research that explores innovative therapy administration techniques. As advancements continue, the potential applications for nucleic acid delivery are expected to expand significantly, reinforcing its market position. This trend suggests that suppliers should prioritise the development of nucleic acid delivery systems to meet the rising demand from both research and clinical sectors.
By End User – Hospitals Dominated, Specialty Clinics Expected to Grow Fastest
The largest end user category in 2025 was Hospitals, with a 43% share of total revenue. Hospitals capture the largest market share for targeted therapies in India, serving as the main providers of these treatments. With advanced oncology facilities, hospitals are equipped to deliver comprehensive cancer care effectively to a growing patient population. Over 2026–2032, Specialty Clinics are expected to post the fastest growth, at a CAGR of 8.5%. Specialty Clinics are emerging as the fastest-growing segment, focusing on specific disease treatments, including targeted therapies. Their specialised approach allows for tailored treatment plans, making them increasingly appealing to patients seeking targeted options. For suppliers, this indicates a need to establish partnerships with specialty clinics to better reach patients interested in targeted therapy solutions.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Targeted Therapy Market Outlook
- Market Size of India Targeted Therapy Market, 2025
- Forecast of India Targeted Therapy Market, 2032
- Historical Data and Forecast of India Targeted Therapy Revenues & Volume for the Period 2022 - 2032F
- India Targeted Therapy Market Trend Evolution
- India Targeted Therapy Market Drivers and Challenges
- India Targeted Therapy Price Trends
- India Targeted Therapy Porter's Five Forces
- India Targeted Therapy Industry Life Cycle
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Therapy Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Small Molecule Drugs for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Biologic Therapies for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By RNA-Based Therapies for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Peptide Therapies for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Disease Indication for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Oncology for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Autoimmune Diseases for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Genetic Disorders for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Hormonal Disorders for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Delivery Mode for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Oral for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Injection/IV for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Nucleic Acid Delivery for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Nasal/Sublingual for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Specialty Clinics for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Research Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Market Revenues & Volume By Biotech Companies for the Period 2022 - 2032F
- India Targeted Therapy Import Export Trade Statistics
- Market Opportunity Assessment By Therapy Type
- Market Opportunity Assessment By Disease Indication
- Market Opportunity Assessment By Delivery Mode
- Market Opportunity Assessment By End User
- India Targeted Therapy Top Companies Market Share
- India Targeted Therapy Competitive Benchmarking By Technical and Operational Parameters
- India Targeted Therapy Company Profiles
- India Targeted Therapy Key Strategic Recommendations
Market Covered
Segments analysed in this report are listed below.
By Therapy Type
- Small Molecule Drugs
- Biologic Therapies
- RNA-Based Therapies
- Peptide Therapies
By Disease Indication
- Oncology
- Autoimmune Diseases
- Genetic Disorders
- Hormonal Disorders
By Delivery Mode
- Oral
- Injection/IV
- Nucleic Acid Delivery
- Nasal/Sublingual
By End User
- Hospitals
- Specialty Clinics
- Research Hospitals
- Biotech Companies
